XuefuZhuyu decoction protected cardiomyocytes against hypoxia/reoxygenation injury by inhibiting autophagy

Xiaowen Shi¹, Haiyan Zhu²*, Yuanyuan Zhang³, Mingmei Zhou¹, Danli Tang⁴ and Huamin Zhang⁴*

Abstract

Background: XuefuZhuyu decoction (XFZY) is a well-known traditional Chinese herbal medicine for the treatment of various cardiovascular diseases, such as unstable angina pectoris and myocardial ischemia-reperfusion injury. However, the mechanism by which XFZY contributes to the amelioration of cardiac injury remains unclear.

Methods: H9C2 cells were cultured under the hypoxic condition for 10 h and reoxygenated for 2 h. In the presence of various concentrations of XFZY for 12 h, the cell viability was measured by MTT assay. The protective effect of XFZY in hypoxia/reoxygenation (H/R) cell model was confirmed by measuring the amount of LDH released into the extracellular fluid. Cell apoptosis was measured by western blotting. The autophagy level of H9C2 cells and the correlative pathway were determined by transmission electron microscopy, Cyto-ID® Autophagy Detection Kit, and western blotting.

Results: In this study, we investigated the effects of XFZY on H/R induced cardiac injury. The results showed that treatment with XFZY significantly inhibited autophagy induced by H/R, with decreased formation of autophagosomes as well as the expression of LC3-II/LC3-I ratio and Beclin 1 after H/R. Importantly, inhibition of autophagy by XFZY resulted in enhanced cell viability and decreased apoptosis. XFZY also inhibited the activation of AMPK and upregulated the phosphorylation of mammalian target of Rapamycin (mTOR).

Conclusions: The cardioprotective effects of XFZY during H/R were mediated by inhibiting autophagy via regulating AMPK-mTOR signaling pathways.

Keywords: XuefuZhuyu decoction, Hypoxia/reoxygenation, Autophagy, Ischemic/reperfusion, mTOR

Background

XuefuZhuyu decoction (XFZY) is a well-known traditional Chinese herbal medicine recorded in the Yi Lin Gai Cuo compiled by Qing-ren Wang in the Qing dynasty (AD 1830). XFZY has multiple effects such as anti-inflammation [1], antioxidant and drug-metabolizing enzymes [2] and angiogenesis modulation [3]. XFZY is very effective in the treatment of various cardiac diseases, such as myocardial fibrosis [4], hypertension [5], unstable angina pectoris [6], atherosclerosis [7] and myocardial ischemia-reperfusion injury [8]. We have recently found that XFZY could ameliorate hypoxia/reoxygenation (H/R) induced cardiac injury. In this study, we established an H/R-induced cardiomyocyte injury model that caused the death of cardiomyocyte H9C2 cells and investigated the mechanisms by which XFZY contributed to the amelioration of cardiomyocyte apoptosis.

Ischemia-reperfusion (I/R) induced myocardial injury is considered to be the main cause of acute myocardial infarction, which is mainly caused by the restoration of
blood flow to the ischemic myocardium. There is increasing evidence that oxidative stress, apoptosis, Ca\textsuperscript{2+} overload, and autophagy is involved in this process [9, 10]. Autophagy is a major catabolic mechanism by which mammalian cells degrade and recycle macromolecules and organelles at the basal level under normal conditions, contributing to maintaining intracellular homeostasis by removing protein aggregates and damaged organelles. However, autophagy plays quite different roles in the myocardial ischemia and reperfusion. During ischemia, a low level of ATP can activate AMP-activated protein kinase (AMPK)-mammalian target of Rapamycin (mTOR) pathway, which leads to autophagy initiation and cardioprotection; while during reperfusion, increased reactive oxygen species could result in the upregulation of Beclin 1 and thus the death of autophagic cells [11].

In this study, low-toxicity XFZY that could be absorbed by small intestine was used as an alternative to drug-containing serum and extraction solution, and then we investigated whether autophagy was involved in XFZY induced cardiomyocyte protection. Our results clearly showed that the treatment with XFZY resulted in a lower autophagic level than negative controls. More importantly, the inhibition of autophagy by XFZY significantly rescued cell viability and decreased apoptosis in H9C2 cells. We also investigated the relationship between autophagy and its upstream regulators. Our results provided a new mechanistic insight into the role of XFZY against H/R-induced cardiomyocyte injury.

**Methods**

**Preparation of XFZY**

XFZY was provided by Beijing Tongrentang (Bozhou) Prepared Slices of Chinese Crude Drugs Co., Ltd., which consisted of 11 herbs, as shown in Table 1. These herbs were macerated for 2-3 h with 4 L of distilled water and decocted for 40 min. The filtrate was collected and the residue was decocted again for 40 min with 2.5 L of distilled water for the collection of filtrate again. The two filtrates were combined and then condensed to 4.3 g/ml. The volume of XFZY solution was diluted to 600 ml with Tyrode's buffer solution (NaCl 8.00 g, KCl 10.28 g, NaHCO\textsubscript{3} 1.00 g, NaH\textsubscript{2}PO\textsubscript{4} 0.05 g, MgCl\textsubscript{2} 0.10 g, CaCl\textsubscript{2} 0.20 g, and glucose 1.00 g; pH 7.4).

Male Sprague-Dawley Rats were maintained under fasting conditions for 12 h before the experiment. Their small intestines were quickly removed under anesthesia, washed with Tyrode buffer solution (0 °C) and cut into four segments of 14 cm each. Each segment was turned inside-out and ligated to form a sac at one end. Then, the sac was filled with Tyrode buffer and incubated in Magnus’ bath for 5 min to reach equilibrium. The buffer was exchanged with XFZY solution (25 mL), and the segment was maintained at 37 °C in a 95%O\textsubscript{2}/5%CO\textsubscript{2} atmosphere. Serosalside solutions containing absorbed constituents (2.5 ml) were drained into tubes after 2 h. XFZY was filtered with a microfiltration membrane (0.22 μm) and stored at -20 °C.

**Chromatographic analysis of XFZY**

High-performance liquid chromatography (HPLC) was performed on an Agilent 1290 UPLC system (Agilent Technologies, Waldbronn, Germany) connected to an Agilent 6520 Q-TOF mass spectrometer (Agilent Corporation, Santa Clara, CA, USA) via an ESI interface. Acetonitrile and methanol (HPLC grade) were purchased from Fisher Scientific (Pittsburg, PA, USA). Formic acid (HPLC grade) was purchased from Damao (Tianjin, China). Water for HPLC was purified by a Milli-Q water purification system (Millipore, Bedford, MA, USA), and polytetrafluoroethylene (PTFE) membranes of 0.2 μm purchased from Millipore (Bedford, MA, USA) were used for processing samples.

The separation was carried out on a ZORBAX SB-C18 column (100 mm × 4.6 mm, 1.8 μm particle size, Agilent) at 50 °C with a flow rate of 0.4 mL/min. The mobile phase was a mixture of 0.1% formic acid-water (A) and acetonitrile (B). The gradient program of the mobile phase was as follows: 0–2 min, 5–15% B; 2–5 min, 15–25% B; 5–7 min, 25–31% B; 7–9 min, 31–40% B; 9–12 min, 40–75% B; and 12–15 min, 75–95% B. The injection volume was 2 μL.

The acquisition parameters of Hybrid quadrupole time-of-flight mass spectrometry (QTOF) were as follows: drying gas (N\textsubscript{2}) flow rate, 10.0 L/min; drying gas temperature, 350 °C; nebulizer gas pressure, 40 psi; capillary voltage, 4500 V; fragmentor voltage, 150 V; skimmer voltage, 65 V; and octopole RF, 750 V. The sample was analyzed in both positive and negative modes.
negative ion modes to provide complementary information for structural identification.

The quasi-molecular ions [M – H]− and [M + H]⁺ were selected as the precursor ions and subjected to target-MS/MS analyses. The collision energy (CE) was set at 15–40 V and the mass range was recorded from m/z 100 to 1000.

**Cell culture**

Rat H9C2 cells obtained from Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, were cultured in high glucose DMEM (Corning, USA) and 10% heat-inactivated fetal bovine serum (Invitrogen, San Diego, CA, USA) supplemented with 100 U/mL penicillin and 100 g/mL streptomycin (Beyotime Institute of Biotechnology, Haimen, China) at 37 °C in a 95% air/5% CO₂ atmosphere. The medium was replaced every 2–3 days, and cells were subcultured or subjected to experimental procedures at 80–90% confluence.

**H/R injury model in vitro**

H/R injury model in vitro was established as previously described [12]. H9C2 cells were incubated in the hypoxic/ischemic chamber (Anaerocult® A mini, Merck) in serum-free and low-glucose DMEM at 37 °C for 10 h in a humidified atmosphere of 5% CO₂ and 95% nitrogen, and then incubated with fresh medium and restored to 95% nitrogen/5% CO₂ for 2 h reoxygenation. At the onset of hypoxia, cardiomyocytes were randomly treated with 4.5, 9 and 18 mg/ml XFZY with Tyrode buffer as a vehicle, respectively, and H9C2 cells cultured under normal conditions in a CO₂ incubator served as negative controls. At the same time, cell model of starvation-rapamycin-induced autophagy was established in H9C2 cells. Cells were incubated in serum-free medium or with rapamycin (500 nm) in the presence or absence of XFZY for 10 h, and the protein expression of LC3 (normalized to that of GAPDH) was assayed.

**Cell viability assay**

Cell viability was determined by MTT cytotoxicity assay. Cells were seeded in 96-well plates at a concentration of 2 × 10⁴ cells/well. After the cells adhered, the medium was replaced with serum-free and low-glucose DMEM (Thermo Fisher Scientific, Beijing, China) or various concentrations (4.5, 9, 18, 36, and 72 mg/ml) of XFZY in low glucose DMEM. After incubation for 48 h, the cytotoxicity of XFZY was assayed by MTT. Cells in each group were cultured under hypoxic conditions for 10 h and reoxygenated for 2 h (H10/R2). Cells were incubated with MTT (0.5 mg/ml) for 4 h at 37 °C, and then the supernatants were carefully removed, and the formazan crystal was dissolved in DMSO and quantified spectrophotometrically at 570 nm. The reduction in optical density was considered to be the decrease in cell viability.

**Measurement of lactate dehydrogenase (LDH) release in culture supernatants**

Cell injury was confirmed by measuring the amount of LDH released into the extracellular fluid from damaged cells after H10/R2 injury. H9C2 cells were plated in 96-well plates as described in the MTT assay. Ten hours later, the amount of LDH was detected by an LDH assay kit (Beyotime Biotechnology, Haimen, China) according to the manufacturer’s instruction with a microplate Reader at 450 nm.

**Transmission electron microscopy**

H9C2 cells were fixed with 2% glutaraldehyde for 15 min and then fixed in 2% glutaraldehyde with 0.1 M Na-Cacodylate/HCl (pH 7.4) for 30 min. They were washed three times with 0.2 M Na Cacodylate/HCl (pH 7.4), fixed with 1% OsO₄–0.15 M Na Cacodylate/ HCl (pH 7.4) for 30 min, and then dehydrated in a growing gradient of ethanol and finally polymerized at 60 °C for 48 h. Samples were cut and analyzed with a JEM 1230 transmission electron microscope (JEOL, Peabody, MA).

**Western blot analysis**

H9C2 cells were harvested, washed twice with cold phosphate-buffered saline (PBS), and kept in RIPA lysis buffer (Beyotime Institute of Biotechnology, Jiangsu, China) for 30 min on ice. Then, the lysates were centrifuged, and the supernatants were collected. The protein concentration was examined by the bicinchoninic acid (BCA) method. Equivalent amounts of protein were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to poly-vinylidene fluoride membranes. The membranes were blocked in Tris-buffered saline and Tween 20 (TBST) containing 3% bovine serum albumin (BSA) for 1 h at room temperature, and incubated with the primary antibodies at 4 °C overnight and then with the second antibody conjugated with horseradish peroxidase for 2 h at room temperature. Then, the membranes were washed in TBST and the signals were visualized using an enhanced chemiluminescent detection kit (Pierce, Rockford, IL). Densitometric values of protein bands were quantified by the IQuantTL software (GE Healthcare, USA).

**Confocal immunofluorescence**

H9C2 cells were seeded into clear bottom imaging tissue culture plates (NEST Biotechnology Co., Ltd., Jiangsu, China). After 24 h of incubation, cells were treated with an equal volume of the vehicle with or without XFZY
(18, 9, or 4.5 mg/mL) for another H10/R2 incubation. Cells were treated with Cyto-ID Autophagy Detection Kit (Enzo Life Sciences, Inc.) according to the manufacturer's instruction. Briefly, cells were washed twice with assay buffer and stained with Cyto-ID and Hoechst 33,342 at 37 °C for 30 min. After incubation, cells were washed again with 1 × assay buffer and immediately analyzed with an Olympus fluorescence microscope.

Statistical analysis
All statistical analyses were performed using GraphPad Prism 5. The results were expressed as mean ± SD. Statistical comparisons were performed using One-way ANOVA, and P values <0.05 were considered statistically significant.

Results
Chromatographic analysis of XFZY
Generally, the components of the decoction are qualitatively identified by the chemical substances from the involved single herbs. A total of nine compounds were identified or tentatively characterized in XFZY by comparing their characteristic high-resolution mass data with that of previous studies [13–16]. The mass error for molecular ions of all identified compounds was within ± 6 ppm, and the total ion chromatograms in negative and positive ion modes were displayed in Fig. 1.

 XFZY protected against H/R injury in cardiomyocytes
In order to determine whether XFZY protected cardiomyocytes against H/R injury, we first examined the toxicity of XFZY to H9C2 cells under normoxic conditions, and then examined that of XFZY after H/R treatment at the toxic concentration. As shown in Fig. 2, 4.5, 9 and 18 mg/ml of XFZY had no toxic effects on H9C2 cells under normoxic conditions, while XFZY exhibited toxicity on H9C2 cells at 36 and 72 mg/ml under normoxic conditions. H/R treatment triggered significant morphological changes of H9C2
cells with reduced cell viability and leakage of cardiac enzymes, which could be reversed by 4.5, 9 and 18 mg/ml of XFZY (Fig. 3a and b). And H9C2 cells treated with 4.5, 9 and 18 mg/ml of XFZY showed no significant morphological changes compared to negative controls. Thus, XFZY protected H9C2 cells against the H/R injury.

**XFZY inhibited apoptosis of cardiomyocytes induced by H/R injury**

To further explore the protection of XFZY against H/R-induced injury, apoptosis protein levels were examined in H9C2 cells treated with H/R and/or XFZY. Figure 4 clearly showed that H/R induced cleavage of the apoptosis-related protein, poly ADP-ribose polymerase (PARP) in H9C2 cells, indicating the activation of apoptosis. However, XFZY attenuated the expression of cleaved PARP, suggesting XFZY to inhibit apoptosis of cardiomyocytes induced by H/R injury. Furthermore, H9C2 cells treated with H10/R2 and XFZY showed a lower RARP activity than that treated only with H10/R2. Thus, XFZY prevented H/R-induced apoptosis in cardiac cells.

**XFZY inhibited autophagy of cardiomyocytes induced by H/R injury**

In order to determine the effect of XFZY on autophagy of cardiomyocytes induced by H/R injury, we analyzed the expression of autophagy marker proteins at different time points during H10/R2. The results clearly showed that the expression of LC3-II increased gradually during hypoxia and reached a peak after reoxygenation for 2 h (Fig. 5). We speculated that inhibition of autophagosomes formation by XFZY could contribute to the survival of H9C2 cells under H/R conditions. Then, we observed ultra-structural changes in H9C2 cells after H/R by transmission electron microscopy and analyzed the expression of autophagy marker proteins LC3-I/II in H9C2 cells under normoxic and H/R conditions by western blot. Figure 6a and c showed that H/R resulted in a
significant increase in LC3-II expression and autophagosomes formation, while XFZY inhibited the transform of LC3-I to LC3-II and the number of autophagosomes compared to H9C2 cells cultured under H/R conditions. H/R also led to the accumulation of autophagic fluorescence (green fluorescence) in H9C2 cells (Fig. 6b). The quantitative analysis of relative autophagic fluorescence intensity showed that XFZY inhibited the continuous accumulation of autophagosomes and the transform of LC3-I to LC3-II after H10/R2. Thus, autophagy could be triggered by H/R in H9C2 cells, and XFZY significantly inhibited the accumulation of autophagosomes.

MAPK/mTOR signaling pathway was involved in the inhibition of autophagy of cardiomyocytes induced by H/R injury
To determine the molecular mechanism of autophagy of cardiomyocytes induced by H/R injury, expressions of a series of upstream proteins, such as AMPK, beclin1, and mTOR, were evaluated. We found that XFZY decreased the phosphorylation of AMPK, beclin1, and LC3-II, but increased that of mTOR, which indicated H/R-induced autophagy to be mediated by inhibition of mTOR expression (Fig. 7). Our results also indicated that inhibition of AMPK could relieve H/R-induced autophagy and protect against cardiac injury.

XFZY inhibited starvation/rapamycin-induced autophagy in cardiomyocytes
Since H/R-induced autophagy could be modulated by inhibiting mTOR signaling in H9C2 cells and partly rescued by XFZY, we hypothesized that XFZY may act as an autophagy inhibitor during energy deprivation and rapamycin-induced autophagy by regulating p-mTOR. Thus, we analyzed the inhibitory effect of XFZY on starvation and rapamycin-induced autophagy. As shown in Fig. 8, the LC3-II/LC3-I to GAPDH ratio was significantly increased by starvation and rapamycin in H9C2 cells, and XFZY inhibited starvation and Rapamycin-induced autophagy at 4.5, 9, and 18 mg/ml. Thus, XFZY inhibited the upstream of the AMPK-mTOR pathway.

Discussion
We speculated that XFZY could inhibit H/R-mediated autophagosome formation, which contributed to the survival of H9C2 cells under H/R conditions. In this study, we investigated the mechanisms by which XFZY protected myocardial H9C2 cells against H/R injury. The results clearly showed that XFZY enhanced cell survival and inhibited apoptosis of cardiomyocytes induced by H/R injury, and also modulated autophagy by regulating the activity of AMPK-mTOR signaling pathway. H/R is one of the main pathological factors for cell injury. Previous studies have demonstrated that the animal model in which myocardial cells exposed to low ATP and oxygen depletion could imitate the part of the internal environment of I/R to test the mechanism of therapy in vivo [17]. Thus, H9C2 cell models exposed to H/R were used to mimic I/R induced cell injury in vitro, which
contributed to developing effective drugs for the treatment of cardiovascular diseases.

Autophagy is considered to be an important cytoprotective mechanism by which excess or damaged organelles are degraded [18]. Mild activation of autophagy can promote the survival of cells, while excessive activation of autophagy can destroy normal proteins and organelles, leading to the death of autophagic cells. Our results showed that excessive autophagy was involved in H/R-induced cardiomyocyte injury, which was inhibited by XFZY due to enhanced viability and inhibition of apoptosis.

Autophagy can be promoted by AMPK, a key energy sensor capable of regulating cellular metabolism.
to maintain energy homeostasis. Conversely, it could be inhibited by mTOR, a central cell-growth regulator that integrates growth factor and nutrient signals [19]. It has been shown that H/R induced down-regulation of p-mTOR via the AMPK-mTOR pathway, as tuberous sclerosis complex1/tuberous sclerosis complex 2 (TSC1/TSC2) protein complex was the major suppressor of the mTOR signaling in H9C2 cells exposed to H/R. Our study revealed how XFZY regulated the AMPK-mTOR pathway of autophagy, and inhibition of autophagy was helpful for the survival of H9C2 cells exposed to H/R. In the starvation/rapamycin-induced cell model, XFZY decreased the ratio of LC3-II/LC3-I under the conditions of ATP depletion. In another model in which autophagy was induced by rapamycin, XFZY inhibited the ratio of LC3-II/LC3-I by inhibiting the fusion of autophagosomes and lysosomes. Thus, XFZY inhibited autophagy in cells under different conditions, the mechanism of which may be related to the upstream of mTOR pathway. We speculated that AMPK was not the specific target of XFZY in vitro, but XFZY did protect H/R-induced cardiac injury through the mTOR pathway. However, further studies are needed to identify the target and active components of XFZY.

XFZY is a classic traditional Chinese medicine for the treatment of cardiovascular diseases. However, the active components of XFZY remain unidentified. The small intestine is the major absorption site for herbal medicines. XFZY can be absorbed by small intestine in a similar way as that for most traditional Chinese medicines. The constituents of XFZY absorbed by the digestive tract may produce therapeutic effects [20, 21]. In this study, we tested the intestinal absorption of XFZY in H/R cell model to reveal its protective activity on H/R injury [8], and the results clearly showed that the intestinal absorption of Chinese herbs may be a potential approach to study the mechanism of Chinese herb compounds in vitro.

XFZY resulted in a delayed apoptosis and highly inhibited autophagy in H9C2 cells exposed to H/R. Previous studies have shown that apoptosis is one of the main factors involved in the ischemic heart diseases, while inhibition of apoptosis is an important therapeutic approach for ischemic heart diseases. Our study showed...
that inhibition of autophagy contributed to the inhibition of apoptosis, thus indicating that inhibition of autophagy could be a potential approach for the treatment of H/R injury.

**Conclusion**

In conclusion, XFZY significantly relieved damage after H/R injury and improved the survival of cardiomyocytes by inhibiting excessive autophagy. The protection of XFZY against H/R-induced cardiomyocyte injury were mediated by inhibiting excessive autophagy via regulating AMPK-mTOR signaling pathways.

**Abbreviations**

BCA: Bicinchoninic acid; BSA: Bovine serum albumin; CE: Collision energy; H/R: Hypoxia/reoxygenation; H10/R2: Hypoxic conditions for 10 h and reoxygenation for 2 h; HPLC: High-performance liquid chromatography; I/R: Ischemia-reperfusion; MI/RI: Myocardial ischemia and reperfusion; mTOR: Mammalian target of rapamycin; PBS: Phosphate-buffered saline; PTFE: Polytetrafluoroethylene; SDS-PAGE: Sodium dodecyl sulfate-polyacrylamide gel electrophoresis; TBST: Tris-buffered saline and Tween 20; XFZY: Xuefu Zhuyu decoction.

**Acknowledgements**

Not applicable.

**Funding**

This work was supported by the National Nature Science Foundation of China (No. 81373792; 81,202,630) and China Postdoctoral Science Foundation (2014 T70201). The authors declare no conflicts of interest.

**Availability of data and materials**

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. All data generated or analyzed during this study are included in this published article.

**Authors’ contributions**

Xiaowen Shi and Mingmei Zhou carried out the experiments. Haiyan Zhu and Huamin-Zhang designed the work. Danli Tang prepared for XFZY and analyzed the composition. Haiyan Zhu, Yuan-Yuan Zhang, and Huamin-Zhang drafted the manuscript and revised it critically. All authors agree to be accountable for all aspects of the work.

**Competing interests**

All of the authors have read and approved the article, and declare that they have no competing financial interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

Not applicable.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Author details**

1. Center for Chinese Medical Therapy and Systems Biology, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, People’s Republic of China. 2. Department of Microbiological & Biochemical Pharmacy, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai 201203, People’s Republic of China. 3. Department of Pharmacology, West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu 610041, People’s Republic of China. 4. Institute of Information on Traditional Chinese Medicine, China Academy of Chinese Medical Sciences, No.16, Nanxiao Road, Dongzhimen, Beijing 100700, People’s Republic of China.

**Received:** 16 February 2017 **Accepted:** 5 June 2017 **Published online:** 19 June 2017

**References**

1. Xing Z, Xia Z, Peng W, Li J, Zhang C, Fu C, et al. Xuefu Zhuyu decoction, a traditional Chinese medicine, provides neuroprotection in a rat model of traumatic brain injury via an anti-inflammatory pathway. Sci Rep. 2016;6:20040.
2. Fan XH, Shi WZ, Cheng YX, Zou J, Yang XF. Effects of xuefu zhuyu decoction on antioxidant and drug-metabolizing enzymes in liver of rats. Zhongguo Zhong Yao Za Zhi. 2014;39(22):4635-6.
3. Song J, Chen WY, Wu LY, Zheng LP, Lin W, Gao D, et al. A microarray analysis of angiogenesis modulation effect of Xuefu Zhuyu decoction on endothelial cells. Chin J Integr Med. 2012;18(7):502-6.
4. Shen Y, Wei H, Jin CL. Effects of Chinese herbal medicine Xuefu Zhuyu decoction on angiotensin II-induced proliferation and extracellular matrix synthesis of rat cardiac fibroblasts. Zhong Xi Yi Jie He Xue Bao. 2011;9(3):313–9.

5. Wang P, Xiong X, Li S. Efficacy and safety of a traditional Chinese herbal formula Xuefu Zhuyu decoction for hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94(42):1850.

6. Yang X, Xiong X, Yang G, Wang J. Chinese patent medicine Xuefu Zhuyu capsule for the treatment of unstable angina pectoris: a systematic review of randomized controlled trials. Complement Ther Med. 2014;22(2):391–9.

7. Lee JH, Hsu WH, Yen TL, Chang NC, Luo YJ, Hisao G, et al. Traditional Chinese medicine, Xue-Fu-Zhu-Yu decoction, potentiates tissue plasminogen activator against thromboembolic stroke in rats. J Ethnopharmacol. 2011;134(3):824–30.

8. Tang D, Liu Z, Zhang H, Sun M, Sui Y. Protective effects of xuefu zhuyu decoction on myocardium ischemia reperfusion injury in rats. Zhongguo Zhong Yao Za Zhi. 2010;35(22):3077–9.

9. Wang A, Zhang H, Liang Z, Xu K, Qiu W, Tian Y, et al. U0126 attenuates ischemia/reperfusion-induced apoptosis and autophagy in myocardium through MEK/ERK/EGR-1 pathway. Eur J Pharmacol. 2016;788:280–5.

10. Seidmayer LK, Juettner V, Kettlewell S, Pavlov EV, Blatter LA, Dediova EN. Distinct mPTP activation mechanisms in ischaemia-reperfusion: contributions of Ca2+, ROS, pH, and inorganic polyphosphate. Cardiovasc Res. 2015;106(2):237–48.

11. Matsui Y, Kyo S, Takagi H, Hsu CP, Hanharan N, Ago T, et al. Molecular mechanisms and physiological significance of autophagy during myocardial ischemia and reperfusion. Autophagy. 2008;4(4):409–15.

12. Osumi K, Nishida M, Shaw D, Smith TW, Marsh JD. NADH measurements in adult rat myocytes during simulated ischemia. Am J Phys. 1911;260:H1743–52.

13. Dong J, Zhu Y, Gao X, Chang Y, Wang M, Zhang P. Qualitative and quantitative analysis of the major constituents in Chinese medicinal preparation Dan-Lou tablet by ultra high performance liquid chromatography/diode-array detector/quadrupole time-of-flight tandem mass spectrometry. J Pharm Biomed Anal. 2013;80:50–62.

14. Xu W, Huang M, Li H, Chen X, Zhang Y, Liu J, et al. Chemical profiling and quantification of Gua-Lou-Gui-Zhi decoction by high performance liquid chromatography/quadrupole-time-of-flight mass spectrometry and ultra-performance liquid chromatography/triple quadrupole mass spectrometry. J Chromatogr B. 2015;986-987:69–84.

15. Shang E, Zhu Z, Liu L, Tang Y, Duan JA. UPLC-QTOF-MS with chemical profiling approach for rapidly evaluating chemical consistency between traditional and dispensing granule decoctions of Tao-Hong-Si-Wu decoction. Chem Cent J. 2012;6(1):143.

16. Liu L, Cheng Y, Zhang H. Phytochemical analysis of anti-atherogenic constituents of Xue-Fu-Zhu-Yu-Tang using HPLC-DAD-ESI-MS. Chem Pharm Bull (Tokyo). 2004;52(11):1295–301.

17. Li YY, Xiang Y, Zhang S, Wang Y, Yang J, Liu W, et al. Thioredoxin-2 protects against oxygen-glucose deprivation/reperfusion injury by inhibiting autophagy and apoptosis in H9C2 cardiomyocytes. Am J Transl Res. 2017;9(3):1471–82.

18. Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88(2):581–609.

19. Chen-Scarabelli C, Agrawal PR, Saravolatz L, Abuniat C, Scarabelli G, Stephanou A, et al. The role and modulation of autophagy in experimental models of myocardial ischemia-reperfusion injury. J Geriatr Cardiol. 2014;11(4):338–48.

20. Chen Y, Wang J, Yuan L, Zhou L, Jia X, Tan X. Interaction of the main components from the traditional Chinese drug pair Chahu-Shaoyao based on rat intestinal absorption. Molecules. 2011;16(11):9600–10.

21. Liu JY, Lee KF, Sze CW, Tong Y, Tang SC, Ng TB, et al. Intestinal absorption and bioavailability of traditional Chinese medicines: A review of recent experimental progress and implication for quality control. J Pharm Pharmacol. 2013;65(5):621–33.